Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 41,169

Document Document Title
WO/2019/177243A1
Disclosed are: a compound represented by chemical formula 1, an organic electronic element comprising a first electrode, a second electrode and an organic material layer between the first electrode and the second electrode; and an electr...  
WO/2019/178383A1
Provided herein are substituted imidazo[1,2-a]pyridines useful as inhibitors of BMP signaling. The invention further provides pharmaceutical compositions of the compounds of the invention. The invention also provides medical uses of subs...  
WO/2019/176732A1
[Problem] To provide a production method capable of easily synthesizing a compound having a structure in which a plurality of tetrahydroisoquinoline rings are linked together, using a reduced number of steps. [Solution] It was found that...  
WO/2019/176791A1
The present invention relates to: a compound represented by formula (I) which has excellent insecticidal activity, miticidal activity and/or nematicidal activity, while having excellent safety, and which is able to be industrially advant...  
WO/2019/174623A1
Disclosed in the present invention are a crystal form of monomethanesulfonate of a deuterated 3-(4,5-substituted aminopyrimidine)phenyl compound as represented by formula I, and a preparation method therefor. The crystal form is highly s...  
WO/2019/174607A1
The present invention relates to a dihydropyridophthalazinone derivative as represented by formula (I), and a preparation method therefor and an application thereof. the R1, R2, R3, m, n, ring A, and ring B in the formula are as defined ...  
WO/2019/175737A1
A series of imidazopyridine and pyrazolopyridine compounds is provided in which carbon hydrogen bonds have been replaced with isotopic carbon-deuterium bonds, syntheses thereof, compositions thereof, and methods of using such compounds a...  
WO/2019/178079A1
Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4a, R4b, X1, X2, X3, X4, X5, and n are as defined herein, pharmaceutical compositions comprising same, and methods of prep...  
WO/2019/174598A1
Provided are certain TRK inhibitors, pharmaceutical compositions thereof, and methods of use thereof.  
WO/2019/178129A1
The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.  
WO/2019/175607A1
The complex chemistry underlying the extensive transformations involved in terpene indole alkaloid synthesis makes identification of the biosynthetic genes challenging. The present invention relates to methods for producing a terpene ind...  
WO/2019/176634A1
Provided are an n-type organic semiconductor material that has better properties and in particular that when used for a transistor exhibits an excellent carrier mobility and a good atmospheric operational stability; an organic semiconduc...  
WO/2019/175897A1
The compounds of Formula I is described herein along with their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof. The compounds described herein, their polymorphs, stereoisomers, tau...  
WO/2019/178484A1
The disclosure provides methods for the acute treatment of depression and/or anxiety, for the enhancement of mTOR (e.g., mTORC1) signaling, and for the reduction of neuroinflammation, comprising administering to a patient in need thereof...  
WO/2019/172200A1
Provided are: a compound which has a higher fluorescence quantum yield and higher light stability than conventional FLAPs; and a polymeric compound including said compound. The problem of the present invention can be solved by providing ...  
WO/2019/173173A1
The present invention provides a method for preparing a compound of Formula (B), Formula (C), or Formula (D): wherein Q is a 3- to 10- membered ring system containing ring members selected from carbon atoms and up to 4 heteroatoms indepe...  
WO/2019/173437A1
Disclosed are compounds of formulas (I) and (III) for treating or preventing a disease or disorder responsive to activation of a D1 dopamine receptor agonist in a mammal in need thereof, wherein R1 R6 and R11 R13 are as defined herein. E...  
WO/2019/173761A1
Disclosed herein are embodiments of a compound that inhibits c-Abl tyrosine kinase (also referred to herein as "c-Abl"). The compound embodiments described herein are novel c-Abl inhibitors that can bind to c-Abl at an allosteric site an...  
WO/2019/172480A1
The present invention relates to a phenanthroline compound and an organic light-emitting element comprising same.  
WO/2019/170063A1
The present invention provides a class of indolizine compounds represented by formula (I), pharmaceutically acceptable salts thereof, a preparation method thereof, and a use thereof. The indolizine compounds have an inhibitory effect on ...  
WO/2019/170055A1
The present invention relates to compounds having CDK4/6 kinase inhibitory activity, a pharmaceutical composition thereof and a use thereof. The present invention relates in particular to compounds represented by formula I, and further r...  
WO/2019/171222A1
Disclosed are new crystalline forms of venetoclax, a selective Bcl2 inhibitor used as a chemotherapy agent, and the processes for preparation of said crystalline forms by treating venetoclax with suitable solvents.  
WO/2019/169539A1
Provided herein are oxa- and aza-tricyclic 4-pyridone-3-carboxylic acid compounds, their manufacture, pharmaceutical compositions comprising them, and their use as medicaments for inhibiting HBsAg secretion and HBV DNA production, and fo...  
WO/2019/170067A1
Disclosed are a crystal form and a salt form of a pyridoimidazole compound, and a preparation method therefor. Further included is the use of the crystal form in preparing anti-influenza virus drugs.  
WO/2019/173082A1
Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular...  
WO/2019/171197A1
Provided is a light emitting element having high luminous efficiency and reliability. This light emitting element includes a host material and a guest material in a light emitting layer. The host material serves to convert triplet excita...  
WO/2019/166639A1
There is provided herein a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein R1, R2, X1, X2, Y1 to Y4, Z1 to Z3 and n have meanings provided in the description.  
WO/2019/168999A1
This present disclosure relates to compounds with ferroptosis inducing activity, a method of treating a subject with cancer with the compounds, and combination treatments with a second therapeutic agent.  
WO/2019/166270A1
The invention relates to an organic electronic device comprising at least one electron transport, electron injection or electron generation layer comprising a compound of Formula (I) wherein all positions which are not linked to a -(A)a-...  
WO/2019/137975A3
The present invention relates to a curable resin composition comprising a curable resin mixture and at least one C2-C3-alkenyl-substituted compound of formula (I) wherein m is 1, 2 or 3; Rm1, Rm2, Rm3 and Rm4 are hydrogen or C6-C14-arylo...  
WO/2019/166937A1
Imidazo[4,5-c]quinoline compounds having a substituent that is attached at the N-1 position by a branched group, single enantiomers of the compounds, pharmaceutical compositions containing the compounds, and methods of making the compoun...  
WO/2019/168135A1
The present invention relates to a method for converting an N,N-dialkylamide compound into an ester compound using, as a catalyst, a complex of a fourth-period transition metal, the complex being obtained by reacting a precursor includin...  
WO/2019/166560A1
The present invention relates to the use of novel nitrification inhibitors of formula (I), which are N-functionalized alkoxy pyrazole compounds. Moreover, the invention relates to the use of compounds of formula (I) as nitrification inhi...  
WO/2019/166269A1
The present invention relates to an organic electronic device comprising, between an anode and a cathode, at least one layer selected from an electron injection layer, an electron transport layer or an electron generation layer, the laye...  
WO/2019/165890A1
Provided herein are chiral compounds that exhibit circularly polarized photoluminescence and electroluminescence and electroluminescent devices and circularly polarized fluorescent probes comprising the same.  
WO/2019/168446A1
The present invention relates to novel compounds of formula (I), which have the properties of a CDK 8/19 inhibitor, and to a pharmaceutical composition containing said compounds, and to the use of said compounds and composition as pharma...  
WO/2019/166824A1
A compound of Formula I : (I) or a pharmaceutically acceptable salt thereof, wherein: each R' is QR1; each Q is independently selected from a bond, -C1-C10 alkylene, -C2-C10 alkenylene, -C(O)-, -C(O)O-, -C(O)N(R1)-, -C(O)N(R1)SO2- -N(R1)...  
WO/2019/166206A1
The present invention relates to an organic material and to an electronic device comprising the organic material, particularly to an electroluminescent device, particularly to an organic light emitting diode (OLED), wherein the semicondu...  
WO/2019/162458A1
The present invention relates to novel compounds which are particularly useful as inhibitors of bacterial glutaminyl cyclases (bacQC); pharmaceutical compositions comprising such compounds; compounds and/or pharmaceutical compositions fo...  
WO/2019/162174A1
The invention relates to novel compounds of formula (I), in which Aa, Ab, Ac, Ad, Q, R1 and n are defined as in the description, to the use thereof as acaricides and/or insecticides for controlling animal pests, and to methods and interm...  
WO/2019/161803A1
The present invention provides a peptidylarginine deiminase PAD4 inhibitor compound represented by formula (I) or a pharmaceutically acceptable salt, stereoisomer and tautomer thereof, and a pharmaceutical composition, a pharmaceutical p...  
WO/2019/120234A3
A bromodomain inhibitor having the structure of formula (I). Also provided in the present invention are a composition and a formulation containing such a compound, and a method of using and preparing the compound.  
WO/2019/165189A1
Disclosed are protein arginine methyltransferase 5 (PRMT5) degradation / disruption compounds including a PRMT5 ligand, a degradation / disruption tag and a linker, and methods for use of such compounds in the treatment of PRMT5-mediated...  
WO/2019/164847A1
Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or d...  
WO/2019/164953A1
The application relates to a compound having Formula X: (X), wherein: the Targeting Ligand is capable of binding to EGFR, including drug resistant forms of EGFR; the Linker is a group that covalently binds to the Targeting Ligand and the...  
WO/2019/160783A1
The present invention relates to Tricyclic Heterocycle Compounds of Formula (I): and pharmaceutically acceptable salts or prodrug thereof, wherein X, Y, Z, R1 and n are as defined herein. The present invention also relates to composition...  
WO/2019/158107A1
Disclosed in the present invention are a heterocyclic compound, an application thereof and a pharmaceutical composition comprising the same. Provided by the present invention are a heterocyclic compound represented by formula I or a phar...  
WO/2019/159202A1
The present invention relates to an antimalarial heterocyclic compound of formula I, dimers thereof and process for the preparation thereof. Further, the present invention relates to a pharmaceutical composition of heterocyclic compound ...  
WO/2019/161320A1
The present disclosure provides methods of treating a cancer in a subject. The method includes a step of measuring a base level of a biomarker selected from a group consisting of hepatocyte growth factor, absolute neutrophil count, c-Met...  
WO/2019/160915A1
The present invention relates to heterobifunctional compounds (degraders), compositions and methods for treating diseases or conditions mediated by Interleukin Receptor-Associated Kinases (IRAKs).  

Matches 1 - 50 out of 41,169